Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801597 | 0.84 | BRD4 (0.33) | BRD4 | |
| SCHEMBL5837020 | 0.83 | ADRA2A (0.32) | CHRNB2CHRNA4MEN1POLBKMT2A | |
| SCHEMBL5859101 | 0.83 | BRD9 (0.31) | BRD4 | |
| SCHEMBL7853080 | 0.83 | CHRNB2 (0.32) | CHRNB2CHRNA4MEN1POLBKMT2A | |
| SCHEMBL27642869 | 0.83 | CHRNB2 (0.32) | CHRNB2CHRNA4MEN1POLBKMT2A | |
| SCHEMBL7034781 | 0.81 | PDCD1 (0.33) | CHRNB2CHRNA4MEN1POLBKMT2A | |
| SCHEMBL28024299 | 0.81 | CHRNB2 (0.31) | CHRNB2CHRNA4MEN1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL5086289 | 0.81 | CHRNB2 (0.31) | CHRNB2CHRNA4MEN1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL28755372 | 0.81 | CHRNB2 (0.31) | CHRNB2CHRNA4MEN1POLBKMT2A | |
| SCHEMBL3688821 | 0.81 | ADRA2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081543-B2 | Bridged biscyclopentadienyl ligands and method of preparation | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20050250956-A1 | Bridged biscyclopentadienyl ligands and method of preparation | RIX FRANCIS C | 2005-11-10 | — | — | US | disclosed |
| US-6960676-B2 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1263764-B1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEM PATENTS INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030220190-A1 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1263764-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | ExxonMobil Chemical Patents Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001058913-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250956-A1 | Bridged biscyclopentadienyl ligands and method of preparation | FDPS, PPIP5K2, DBF4 | CHRNB2 4385/4885CHRNA4 2837/4885MEN1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.